Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Paul N. Mudd"'
Autor:
David Staskin, Jeffrey Frankel, Susann Varano, Michael Kennelly, Diane K. Newman, Matt T. Rosenberg, Denise D. Shortino, Rachael A. Jankowich, Paul N. Mudd Jr
Publikováno v:
International Journal of Clinical Practice, Vol 2022 (2022)
Background. Overactive bladder (OAB) is characterized by urgency and frequency with (OAB wet) or without (OAB dry) urge urinary incontinence (UUI). In the phase 3 EMPOWUR trial, vibegron—a selective β3-adrenergic receptor agonist for the treatment
Externí odkaz:
https://doaj.org/article/a1208647e958488387dc535f657fb93d
Autor:
Benjamin M. Brucker, MD, Jennifer King, PharmD, Paul N. Mudd, Jr, PharmD, MBA, Kimberly McHale, PhD
Publikováno v:
Current Therapeutic Research, Vol 96, Iss , Pp 100674- (2022)
ABSTRACT: Background: The β3-adrenergic agonists vibegron and mirabegron have shown favorable safety profiles and efficacy for the treatment of overactive bladder. However, β-adrenergic receptors are also found outside the bladder, which could lead
Externí odkaz:
https://doaj.org/article/c7a57a7f5142488d923103c5b5cfabfd
Autor:
Denise Shortino, Thomas Rhodes, Cynthia J. Girman, Elizabeth Thomas, Michael J. Kennelly, Paul N. Mudd
Publikováno v:
Advances in Therapy
Background In the absence of head-to-head trials, we performed an indirect treatment comparison of the β3-adrenergic agonists vibegron and mirabegron in the treatment of overactive bladder (OAB). Methods PubMed, Embase, and Cochrane Library were sea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40f64ee91efc82141ad2df07410a5250
https://doi.org/10.1007/s12325-021-01902-8
https://doi.org/10.1007/s12325-021-01902-8
Publikováno v:
Journal of gerontological nursing. 48(7)
The current study assessed the impact of urinary incontinence (UI) on residents, staff, care processes, and quality measures in long-term care (LTC) settings. A 70-question quantitative online survey was sent to directors of nursing (DONs) who had wo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb13fb7e17c36f02e3f3227df530b602
https://pubmed.ncbi.nlm.nih.gov/35771072
https://pubmed.ncbi.nlm.nih.gov/35771072
Autor:
Jeffrey Frankel, David R. Staskin, Susann Varano, Rachael Jankowich, Denise Shortino, Paul N. Mudd
Publikováno v:
Drugs & Aging
Background Overactive bladder (OAB) is common among older adults. The efficacy and safety of vibegron for the treatment of OAB were demonstrated in the international, phase III EMPOWUR trial. This subpopulation analysis from EMPOWUR assessed the effi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f13652957bd5e6219fee7bf4b3d0785
http://europepmc.org/articles/PMC7882560
http://europepmc.org/articles/PMC7882560
Publikováno v:
PharmacoEconomics. 40(10)
Overactive bladder (OAB) is associated with considerable clinical and economic burden. Treatment of patients with OAB using anticholinergics is limited by tolerability issues and increased anticholinergic burden, which is associated with increased ri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::326e827f6fcaf53e5a1862ce19a9c2df
https://pubmed.ncbi.nlm.nih.gov/35881325
https://pubmed.ncbi.nlm.nih.gov/35881325
Publikováno v:
Drugs in context. 11
Few randomized controlled trials evaluate the long-term efficacy and safety of pharmacotherapy for overactive bladder (OAB). This network meta- analysis compares the long-term (52-week) efficacy and safety of vibegron, mirabegron and anticholinergics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e553c9ddce4f4ec431ca0d4e82fde3c4
https://pubmed.ncbi.nlm.nih.gov/36303599
https://pubmed.ncbi.nlm.nih.gov/36303599
Autor:
Julie J. Paik, Greg Lubin, Austin Gromatzky, Paul N. Mudd, Jr., Manish P. Ponda, Lisa Christopher-Stine
Publikováno v:
Clinical and Experimental Rheumatology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b0618df2b2b47fa9296ea1f82ace86d
https://doi.org/10.55563/clinexprheumatol/hxin6o
https://doi.org/10.55563/clinexprheumatol/hxin6o
To evaluate the cost-effectiveness of vibegron compared with other oral pharmacologic therapies as treatment for overactive bladder (OAB). A semi-Markov model with monthly cycles was developed to support a lifetime horizon of vibegron 75 mg from a US
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::926af136ad8f06a007ae67d742f62220
Publikováno v:
Current therapeutic research, clinical and experimental. 96
The βThis study assessed the selectivity of vibegron and mirabegron for β-adrenergic receptors and the maximal effect and potency for βFunctional cellular assays were performed using Chinese hamster ovary-K1 cells expressing βActivation of βVibe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5b55f17899a96524dea43a1692de3ab2
https://pubmed.ncbi.nlm.nih.gov/35693456
https://pubmed.ncbi.nlm.nih.gov/35693456